Form 4: Neurocrine Biosciences Executive David Boyer Reports Stock Transactions

David Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Summary

• On February 8, 2025, David Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, had 1,329 shares of common stock vest as part of a restricted stock unit (RSU) award.
• On February 10, 2025, Boyer sold 700 shares of Neurocrine Biosciences common stock at a weighted average price of $118.3144 per share.
• The sales were executed under a pre-existing Rule 10b5-1 trading plan adopted on June 10, 2021.
• Following these transactions, Boyer directly owns 1,998 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, as it simply reflects routine financial activity.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. The use of 10b5-1 trading plans allows insiders to sell shares while mitigating concerns about insider trading.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include restricted stock units that vest over time.
• The use of 10b5-1 trading plans is a standard practice among executives to manage their stock sales and avoid accusations of insider trading.
• Comparing Boyer's transactions to those of executives at similar-sized biotech companies (e.g., BioMarin, Incyte) could provide context on the scale and frequency of such transactions.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The vesting of RSUs is part of the executive's compensation package and aligns their interests with those of the shareholders.

Key Dates

Keywords

Neurocrine Biosciences, David Boyer, NBIX, Form 4, Stock Sale, Restricted Stock Unit, 10b5-1 Trading Plan, Executive Compensation, Insider Trading